Pharmaceutical

Unlocking the Future: Essential Insights into the Shifting Landscape of Pharmaceutical Litigation

by

Boston, MA – As the pharmaceutical industry continues to evolve, so too does the landscape of pharmaceutical litigation. With a keen eye on these trends, industry experts anticipate several key developments that will shape the future of this legal arena. First and foremost, the rise of generic drugs is expected to contribute to an increase in pharmaceutical litigation. With more generic versions of brand-name drugs entering the market, patent disputes and allegations of product liability are likely to ensue. Additionally, as generic drug manufacturers seek to capitalize on market opportunities, they may face their own … Read more

Pharmaceutical Industry Group Takes Legal Action Against Florida’s Prescription Drug Importation Program

by

MIAMI, Florida – The Pharmaceutical Research and Manufacturers of America is reportedly preparing to file another lawsuit against Florida’s FDA-approved program to import prescription drugs from Canada, according to an unnamed source cited by Endpoints News. This legal action comes after the FDA recently approved Florida’s Canadian Prescription Drug Importation Program, a two-year initiative aimed at lowering drug prices for American consumers by importing certain prescription drugs from Canada. Under the program, Florida’s Agency for Health Care Administration must ensure the authenticity and compliance of the imported drugs with FDA standards. The program is being … Read more

Pharmaceutical Company PDL BioPharma Files Lawsuit Against Eli Lilly and Company Over Alzheimer’s Treatment Compensation

by

INDIANAPOLIS, IN — Nevada-based company PDL BioPharma, Inc. has filed a lawsuit against Eli Lilly and Company in the U.S. District Court for the Southern District of Indiana. PDL alleges that Eli Lilly used its technology to develop an Alzheimer’s disease treatment without compensating PDL. According to the lawsuit filed on December 21, 2023, PDL claims that Eli Lilly used its antibody humanization technology to create donanemab, a treatment for Alzheimer’s. Donanemab is expected to receive FDA approval in the first quarter of 2024. The lawsuit refers to a 2000 agreement between Eli Lilly and … Read more